CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

On average, prognosticators tracking CRISPR stock were expecting the ... BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps ...

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

On average, prognosticators tracking CRISPR stock were expecting the ... BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps ...